Amplia Therapeutics launched a fully underwritten entitlement offer on a 2-for-5 basis to raise approximately $4.3 million.
Priced at 5.5 cents per new share, this entails a 35.3% discount to the previous traded price.
The funds will fuel crucial development initiatives, such as the Phase 2a ACCENT trial, the production of narmafotinib, and an investigator-initiated trial in ovarian cancer.
The proceeds will also support ongoing trials and product development, with interim ACCENT trial results expected in the third quarter.
Claim Now
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments
Great article, would you like to share it?